ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 112 filers reported holding ACLARIS THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.89 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,160,010 | -28.6% | 1,337,082 | +8.1% | 0.00% | -50.0% |
| Q2 2023 | $12,831,934 | +42.3% | 1,237,409 | +11.0% | 0.00% | +100.0% |
| Q1 2023 | $9,016,890 | +53974.3% | 1,114,572 | +5.3% | 0.00% | -50.0% |
| Q4 2022 | $16,675 | -99.9% | 1,058,748 | +2.9% | 0.00% | 0.0% |
| Q3 2022 | $16,192,000 | +21.2% | 1,028,723 | +7.5% | 0.00% | 0.0% |
| Q2 2022 | $13,362,000 | -8.4% | 957,216 | +13.1% | 0.00% | 0.0% |
| Q1 2022 | $14,591,000 | +24.1% | 846,391 | +4.7% | 0.00% | +100.0% |
| Q4 2021 | $11,755,000 | -17.9% | 808,462 | +1.6% | 0.00% | -50.0% |
| Q3 2021 | $14,324,000 | +13.5% | 795,826 | +10.7% | 0.00% | 0.0% |
| Q2 2021 | $12,621,000 | +32.9% | 718,757 | +90.7% | 0.00% | +100.0% |
| Q1 2021 | $9,496,000 | +351.8% | 376,864 | +16.0% | 0.00% | – |
| Q4 2020 | $2,102,000 | +103.5% | 324,976 | -19.2% | 0.00% | – |
| Q3 2020 | $1,033,000 | +54.6% | 402,072 | -2.5% | 0.00% | – |
| Q2 2020 | $668,000 | +9.5% | 412,575 | -29.7% | 0.00% | – |
| Q1 2020 | $610,000 | -72.2% | 587,094 | -49.5% | 0.00% | – |
| Q4 2019 | $2,196,000 | +314.3% | 1,162,366 | +136.7% | 0.00% | – |
| Q3 2019 | $530,000 | -50.2% | 491,116 | +1.0% | 0.00% | – |
| Q2 2019 | $1,064,000 | -62.0% | 486,085 | +4.1% | 0.00% | -100.0% |
| Q1 2019 | $2,797,000 | -50.2% | 467,093 | -38.5% | 0.00% | 0.0% |
| Q4 2018 | $5,616,000 | +40.9% | 760,014 | +176.7% | 0.00% | 0.0% |
| Q3 2018 | $3,987,000 | -25.1% | 274,646 | +3.0% | 0.00% | -50.0% |
| Q2 2018 | $5,325,000 | +24.1% | 266,653 | +8.9% | 0.00% | +100.0% |
| Q1 2018 | $4,290,000 | -22.9% | 244,870 | +8.5% | 0.00% | -50.0% |
| Q4 2017 | $5,565,000 | +1.7% | 225,673 | +6.4% | 0.00% | 0.0% |
| Q3 2017 | $5,471,000 | +40.4% | 212,009 | +47.5% | 0.00% | 0.0% |
| Q2 2017 | $3,896,000 | +10.7% | 143,697 | +21.7% | 0.00% | +100.0% |
| Q1 2017 | $3,519,000 | +24.8% | 118,036 | +13.6% | 0.00% | 0.0% |
| Q4 2016 | $2,820,000 | +115.4% | 103,910 | +103.2% | 0.00% | 0.0% |
| Q3 2016 | $1,309,000 | +44.6% | 51,145 | +4.3% | 0.00% | – |
| Q2 2016 | $905,000 | +10.5% | 49,025 | +13.4% | 0.00% | – |
| Q1 2016 | $819,000 | -16.9% | 43,246 | +18.3% | 0.00% | -100.0% |
| Q4 2015 | $985,000 | – | 36,567 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |